Zonisamide - Revision history

Prab: CSV import

2025-02-20T01:48:50Z

CSV import

← Older revision		Revision as of 01:48, 20 February 2025
Line 43:		Line 43:
	[[Category:Sulfonamides]]		[[Category:Sulfonamides]]
	[[Category:Epilepsy treatment]]		[[Category:Epilepsy treatment]]
			<gallery>
			File:Zonisamide structure.svg\|Zonisamide
			File:Zonisamide molecule ball.png\|Zonisamide
			</gallery>

Prab: CSV import

2024-12-11T03:01:05Z

CSV import

← Older revision		Revision as of 03:01, 11 December 2024
Line 1:		Line 1:
	{{~~svg-image}}~~		{{Short description\|Overview of the use of Zonisamide in medical treatment}}
	~~'''Zonisamide''' is an antiepileptic drug used primarily for~~ the ~~treatment~~ of ~~epilepsy. It belongs to a class of medications known as sulfonamides and has a unique mechanism of action that distinguishes it from other antiepileptic drugs.~~ Zonisamide ~~is effective~~ in ~~managing partial seizures~~, ~~with or without secondary generalization, in adults and children~~.		{{Drugbox
			\| Verifiedfields = changed
			\| verifiedrevid = 477002646
			\| IUPAC_name = 1,2-benzisoxazole-3-methanesulfonamide
			\| image = Zonisamide structure.svg
			\| width = 200px
			}}

	~~==Mechanism~~ of ~~Action==~~		'''Zonisamide''' is a medication primarily used as an adjunctive therapy in the treatment of [[epilepsy]]. It is classified as a [[sulfonamide]] and is known for its anticonvulsant properties. Zonisamide is effective in managing partial seizures and is sometimes used off-label for other neurological conditions.
	~~Zonisamide works by inhibiting sodium and calcium channels, which decreases neuronal hyperexcitability~~. It is ~~also thought to have an effect on neurotransmitter release, further contributing to~~ its ~~antiepileptic~~ properties. ~~The exact mechanism, however,~~ is ~~not fully understood~~.

	==~~Pharmacokinetics~~==		==Pharmacology==
	~~After oral administration, zonisamide is well absorbed from~~ the ~~gastrointestinal tract. It has a bioavailability~~ of ~~nearly 100%~~ and ~~reaches peak plasma concentrations within 2 to 5 hours~~. ~~Zonisamide is primarily metabolized in~~ the ~~liver and has a half-life~~ of ~~approximately 60 hours~~, ~~allowing for once or twice daily dosing. It is excreted both in urine and feces~~.		Zonisamide works by stabilizing neuronal membranes and suppressing neuronal hypersynchronization through the inhibition of voltage-sensitive sodium and calcium channels. It also modulates the release of neurotransmitters, which contributes to its anticonvulsant effects.

	==Indications==		==Indications==
	Zonisamide is indicated for the treatment of partial seizures in adults ~~and children~~. It ~~can be~~ used ~~as monotherapy or~~ in combination with other antiepileptic drugs.		Zonisamide is indicated for the treatment of partial seizures in adults with epilepsy. It is often used in combination with other antiepileptic drugs (AEDs) when monotherapy is insufficient.

	==~~Adverse~~ Effects==		==Dosage and Administration==
	Common ~~adverse~~ effects of zonisamide include drowsiness, ~~dizziness~~, ~~headache~~, and ~~nausea~~. ~~Less frequently, it may cause cognitive impairment~~, kidney stones~~, weight loss~~, and ~~hypersensitivity~~ reactions. ~~Due to its sulfonamide structure, zonisamide carries a risk~~ of ~~serious skin reactions, such as Stevens-Johnson syndrome~~.		The dosage of zonisamide is typically individualized based on the patient's response and tolerance. It is usually started at a low dose and gradually increased. The medication is available in capsule form and is taken orally.

			==Side Effects==
			Common side effects of zonisamide include dizziness, drowsiness, headache, nausea, and loss of appetite. Serious side effects can include metabolic acidosis, kidney stones, and severe skin reactions. Patients should be monitored for signs of depression or suicidal thoughts.

	==Contraindications==		==Contraindications==
	Zonisamide is contraindicated in patients with a known hypersensitivity to sulfonamides. Caution is advised in patients with renal or ~~hepatic impairment, as well as in those with~~ a history of kidney stones.		Zonisamide is contraindicated in patients with a known hypersensitivity to sulfonamides. Caution is advised in patients with renal impairment or a history of kidney stones.

	==~~Drug Interactions~~==		==Mechanism of Action==
	Zonisamide's ~~plasma concentration can be affected by other drugs. Enzyme inducers, such as phenytoin~~ and ~~carbamazepine~~, ~~can decrease zonisamide levels, while enzyme inhibitors like ketoconazole can increase its levels. Additionally, zonisamide can increase~~ the ~~levels~~ of ~~other antiepileptic drugs~~, ~~such as phenytoin and carbamazepine~~.		Zonisamide's mechanism of action involves the blockade of sodium and calcium channels, which reduces the repetitive firing of neurons. It also has a weak inhibitory effect on carbonic anhydrase, which may contribute to its efficacy in seizure control.

	==~~Dosage~~ and ~~Administration~~==		==Research and Development==
	~~The starting dose of zonisamide~~ is ~~typically low, gradually increasing to~~ the ~~optimal dose. For adults, the initial dose is usually 100 mg daily, with increments~~ of ~~100 mg every two weeks~~, ~~up to a usual maintenance dose of 300 to 500 mg daily~~. ~~In children, dosing is based on body weight~~.		Ongoing research is exploring the potential use of zonisamide in other neurological disorders, such as [[Parkinson's disease]] and [[migraine]] prophylaxis. Its neuroprotective properties are also being investigated.

	==~~Pharmacological Properties~~==		==Also see==
	~~Zonisamide's unique pharmacological properties, including its broad spectrum of antiepileptic activity and favorable pharmacokinetic profile, make it a valuable option in the treatment of epilepsy.~~		* [[Epilepsy]]
			* [[Anticonvulsant]]
			* [[Sodium channel blocker]]
			* [[Calcium channel blocker]]

	==~~Conclusion~~==		==References==
	Zonisamide is an effective and generally well-tolerated antiepileptic drug with a unique mechanism of action. Its role in the management of partial seizures, both as monotherapy and as part of combination therapy, is well established. However, like all medications, it must be used cautiously, considering potential adverse effects and interactions with other drugs.		{{Reflist}}

	[[Category:~~Antiepileptic drugs~~]]		[[Category:Anticonvulsants]]
	[[Category:Sulfonamides]]		[[Category:Sulfonamides]]
	~~{{stubd}}~~		[[Category:Epilepsy treatment]]

Prab at 21:00, 3 April 2024

2024-04-03T21:00:51Z

New page

{{svg-image}}
'''Zonisamide''' is an antiepileptic drug used primarily for the treatment of epilepsy. It belongs to a class of medications known as sulfonamides and has a unique mechanism of action that distinguishes it from other antiepileptic drugs. Zonisamide is effective in managing partial seizures, with or without secondary generalization, in adults and children.

==Mechanism of Action==
Zonisamide works by inhibiting sodium and calcium channels, which decreases neuronal hyperexcitability. It is also thought to have an effect on neurotransmitter release, further contributing to its antiepileptic properties. The exact mechanism, however, is not fully understood.

==Pharmacokinetics==
After oral administration, zonisamide is well absorbed from the gastrointestinal tract. It has a bioavailability of nearly 100% and reaches peak plasma concentrations within 2 to 5 hours. Zonisamide is primarily metabolized in the liver and has a half-life of approximately 60 hours, allowing for once or twice daily dosing. It is excreted both in urine and feces.

==Indications==
Zonisamide is indicated for the treatment of partial seizures in adults and children. It can be used as monotherapy or in combination with other antiepileptic drugs.

==Adverse Effects==
Common adverse effects of zonisamide include drowsiness, dizziness, headache, and nausea. Less frequently, it may cause cognitive impairment, kidney stones, weight loss, and hypersensitivity reactions. Due to its sulfonamide structure, zonisamide carries a risk of serious skin reactions, such as Stevens-Johnson syndrome.

==Contraindications==
Zonisamide is contraindicated in patients with a known hypersensitivity to sulfonamides. Caution is advised in patients with renal or hepatic impairment, as well as in those with a history of kidney stones.

==Drug Interactions==
Zonisamide's plasma concentration can be affected by other drugs. Enzyme inducers, such as phenytoin and carbamazepine, can decrease zonisamide levels, while enzyme inhibitors like ketoconazole can increase its levels. Additionally, zonisamide can increase the levels of other antiepileptic drugs, such as phenytoin and carbamazepine.

==Dosage and Administration==
The starting dose of zonisamide is typically low, gradually increasing to the optimal dose. For adults, the initial dose is usually 100 mg daily, with increments of 100 mg every two weeks, up to a usual maintenance dose of 300 to 500 mg daily. In children, dosing is based on body weight.

==Pharmacological Properties==
Zonisamide's unique pharmacological properties, including its broad spectrum of antiepileptic activity and favorable pharmacokinetic profile, make it a valuable option in the treatment of epilepsy.

==Conclusion==
Zonisamide is an effective and generally well-tolerated antiepileptic drug with a unique mechanism of action. Its role in the management of partial seizures, both as monotherapy and as part of combination therapy, is well established. However, like all medications, it must be used cautiously, considering potential adverse effects and interactions with other drugs.

[[Category:Antiepileptic drugs]]
[[Category:Sulfonamides]]
{{stubd}}